Using a two-dimensional display to guide selection of citations

Citations can be plotted in two-dimensions using date of publication and projected quality of the article or the journal it is published in. In this demonstration, quality is projected by the quality of the journal as measured by the Article Influence (AI) Score
Example using list of PMIDs from the trials included in the meta-analysis by Abourbih (2009) (does not include subsequently published ACCORD trial) This frontier performs best when it is wide.
Example using list of PMIDs from the trials included in the meta-analysis by Kansagara (2011)
Example using list of PMIDs from the trials included in the meta-analysis by Musini (2009) This frontier performs best when it is wide.
Input type:
Include related citations:
Frontier width:

Frontier width?

  • 0.52 is the width between the NEJM and JAMA
  • 0.55 is the width between the JAMA and the Annals of Internal Medicine
Privilege evidence-based sources:

Privilege evidence-based sources?

  • If clicked, then the article influence score of articles by known providers of evidence-based resources such as the Cochrane, U.S. Preventive Services Task Force, and others, will be set equal to JAMA.
  • This option has not been formally tested. It may cause trials with article influence less than JAMA and published between the date of the search by the evidence-based review and the date of publication of the review to be removed from the frontier.
Abstract required:
Citation to highlight
Options for publication:
Color graphics:   -  Citation start number
- - - Please click once.
You are not using FireFox; you will not see an extract of the abstract when you hover over the citations in the plot. However, you will see an extract when you hover over the PMID.


The frontier is the red band.
The frontier is defined as containing those trials for which there are no trials both more recent and published in a journal with a AI Score higher than the specified width of the frontier.
Preferred region Avoid region 1 2 3 Frontier Sorry, your browser does not support inline SVG.

* Estimated by the natural log of the article influence score of the journal that the citation is published in.

Citations found

Total: 6


Hypothesis: These studies are considered in the Frontier and should be reviewed by a clinician needing to make a decision.
  1. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005. PMID: 16310551 AI Score: 14.57
  2. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999. PMID: 10438259 AI Score: 21.64
  3. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987. PMID: 3313041 AI Score: 21.64

Citations not on frontier

Hypothesis: These citations are considered outside of the frontier and could safely be ignored by a clinician needing to make a decision.
  1. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002. PMID: 12433762 AI Score: 6.287
  2. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000. PMID: 10880410 AI Score: 6.02
  3. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med. 1993. PMID: 8435186 AI Score: 1.628
Additional citations below the limits of the plot.
    No citations

Article influence score not available

    No citations